The hypotheses generated in the present study therefore support the expanded investigation of IDH1 as a prognostic biomarker for PRAD, particularly complex PRADs like mCRPC, in a larger clinical cohort. The gene discussed is IDH1; the disease is prostate adenocarcinoma.